Analyst upgrades and downgrades can have a significant impact on stock prices. Despite the opportunity for short-term earnings generated by these stocks, analysts may overestimate
A drone is an unmanned aircraft. A drone is more commonly referred to as an unmanned aerial vehicle (UAV) or an unmanned aircraft system (UAS).
Semiconductor stocks had an outstanding 2021. The industry grew to an unprecedented height in the wake of the growing attention of superpowers toward this specific
PetroChina Company Ltd. (NYSE: PTR) is a giant in the energy sector. The company is one of the largest oil and gas producers in the
The markets sometimes become cruel, as the companies which have got an excellent portfolio on the development side depict unimpressive performance on the financial front.
Society Pass Inc. (SOPA), a loyalty and data marketing ecosystem, closed Monday’s regular session at $3.64 after surging 11.31% during the day. In the premarket
AnPac Bio-Medical Science Co., Ltd. (ANPC), a biotechnology company, declined 4.36% in Friday’s regular trading session to close the day at $0.47. In the premarket
At last check Ocugen Inc. (OCGN) stock had plunged by-11.92% to $9.61 in premarket trading session. OCGN stock previously closed at $10.91 losing -12.79%. The
KeyBanc maintained its Magna International [MGA] rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research note
Jefferies took its Medifast [MED] rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research note
RBC Capital took its American Eagle Outfitters [AEO] rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from $23,
KeyBanc maintained its Nike [NKE] rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note dated
Raymond James took its Atlantic Capital [ACBI] rating to the equivalent of Outperform from Market Perform, in a research note dated 2021-01-25. Other analysts also
KeyBanc maintained its Tapestry [TPR] rating to the equivalent of Overweight but changed the price target to $38.0 from $35, in a research note dated
KeyBanc maintained its Silgan Hldgs [SLGN] rating to the equivalent of Overweight but changed the price target to $40.0 from $39, in a research note
Goldman Sachs took its Glu Mobile [GLUU] rating to the equivalent of Neutral from Buy, and the price target to $10.4, in a research note
Goldman Sachs took its Imax [IMAX] rating to the equivalent of Neutral from Buy, and the price target to $17.9 from $15, in a research
Truist Securities took its Magnite [MGNI] rating to the equivalent of Hold from Buy, and the price target to $37.0 from $12, in a research
HC Wainwright & Co. maintained its Xenetic Biosciences [XBIO] rating to the equivalent of Buy but changed the price target to $5.0 from $2, in
Credit Suisse took its Ternium [TX] rating to the equivalent of Outperform from Neutral, and the price target to $41.5, in a research note dated
Jefferies took its SolarWinds [SWI] rating to the equivalent of Hold from 18, and the price target to $15.0 from $Buy, in a research note
Credit Suisse launched its Scholar Rock Holding [SRRK] rating to the equivalent of Outperform and assigned the price target of $65.0, in a research note
Baird took its Spirit AeroSystems Hldgs [SPR] rating to the equivalent of Outperform from Neutral, and the price target to $53.0 from $23, in a
RBC Capital took its SM Energy [SM] rating to the equivalent of Outperform from Sector Perform, and the price target to $12.0, in a research
Barclays launched its Madison Square Garden [MSGS] rating to the equivalent of Overweight and assigned the price target of $224.0, in a research note dated
Jefferies took its Mimecast [MIME] rating to the equivalent of Hold from Buy, and the price target to $55.0, in a research note dated 2021-01-11.
Barclays took its Liberty SiriusXM Gr [LSXMA] rating to the equivalent of Overweight from Equal Weight, and the price target to $55.0 from $39, in
Jefferies took its LivePerson [LPSN] rating to the equivalent of Hold from Buy, and the price target to $65.0 from $55, in a research note
HC Wainwright & Co. maintained its Kopin [KOPN] rating to the equivalent of Buy but changed the price target to $3.5 from $2, in a
HSBC took its Johnson Controls Intl [JCI] rating to the equivalent of Hold from Buy, and the price target to $52.0, in a research note
HC Wainwright & Co. maintained its Intellicheck [IDN] rating to the equivalent of Buy but changed the price target to $18.0 from $12, in a
Goldman Sachs took its Globant [GLOB] rating to the equivalent of Neutral from Buy, and the price target to $210.0 from $190, in a research
Stifel launched its Guardant Health [GH] rating to the equivalent of Buy and assigned the price target of $175.0, in a research note dated 2021-01-11.
HC Wainwright & Co. maintained its ESSA Pharma [EPIX] rating to the equivalent of Buy but changed the price target to $17.0 from $10, in
HC Wainwright & Co. maintained its Collegium Pharmaceutical [COLL] rating to the equivalent of Buy but changed the price target to $33.0 from $29, in
HC Wainwright & Co. maintained its Chimerix [CMRX] rating to the equivalent of Buy but changed the price target to $16.0 from $7, in a
HC Wainwright & Co. maintained its BridgeBio Pharma [BBIO] rating to the equivalent of Buy but changed the price target to $87.0 from $64, in
HC Wainwright & Co. maintained its Applied DNA Sciences [APDN] rating to the equivalent of Buy but changed the price target to $18.0, in a
BMO Capital took its Andersons [ANDE] rating to the equivalent of Market Perform from Outperform, and the price target to $26.0 from $24, in a
Baird took its Walgreens Boots Alliance [WBA] rating to the equivalent of Outperform from Neutral, and the price target to $55.0 from $41, in a
Jefferies took its Datadog [DDOG] rating to the equivalent of Buy from Hold, in a research note dated 2021-01-11. Some new analysts also started their
Jefferies took its CrowdStrike Holdings [CRWD] rating to the equivalent of Buy from Hold, in a research note dated 2021-01-11. Other analysts also revised their
Canaccord Genuity took its Intersect ENT [XENT] rating to the equivalent of Buy from Hold, and the price target to $25.0 from $18, in a
Evercore ISI Group took its Jack Henry & Associates [JKHY] rating to the equivalent of In-Line from Underperform, and the price target to $165.0 from
BMO Capital took its Archer-Daniels Midland [ADM] rating to the equivalent of Market Perform from Outperform, and the price target to $56.0 from $51, in
Baird took its Albany International [AIN] rating to the equivalent of Neutral from Outperform, and the price target to $79.0 from $70, in a research
KeyBanc maintained its Shopify [SHOP] rating to the equivalent of Overweight but changed the price target to $1300 from $1250, in a research note dated
Piper Sandler took its Anaplan [PLAN] rating to the equivalent of Overweight from Neutral, and the price target to $87 from $66, in a research
Piper Sandler took its Salesforce.com [CRM] rating to the equivalent of Neutral from Overweight, and the price target to $242 from $278, in a research
JP Morgan took its Boot Barn Holdings [BOOT] rating to the equivalent of Overweight from Neutral, and the price target to $60 from $46, in
RBC Capital took its Royal Gold [RGLD] rating to the equivalent of Outperform from Sector Perform, and the price target to $150 from $155, in
Rosenblatt maintained its Roku [ROKU] rating to the equivalent of Buy but changed the price target to $420.0 from $260, in a research note dated
Goldman Sachs took its Brown & Brown [BRO] rating to the equivalent of Buy from Neutral, and the price target to $54.0 from $49, in
Jefferies took its CVS Health [CVS] rating to the equivalent of Buy from Hold, and the price target to $90.0, in a research note dated
BMO Capital took its CareTrust REIT [CTRE] rating to the equivalent of Outperform from Market Perform, and the price target to $26.0, in a research
Wells Fargo took its Amphastar Pharmaceuticals [AMPH] rating to the equivalent of Equal-Weight from Overweight, and the price target to $21.0, in a research note
Piper Sandler took its Chevron [CVX] rating to the equivalent of Overweight from Neutral, and the price target to $113.0, in a research note dated
Goldman Sachs took its Arthur J. Gallagher [AJG] rating to the equivalent of Neutral from Buy, and the price target to $129.0 from $123, in
Evercore ISI Group took its Tesla [TSLA] rating to the equivalent of In-Line from Underperform, and the price target to $650.0, in a research note
Credit Suisse took its Envista Holdings [NVST] rating to the equivalent of Outperform from Neutral, in a research note dated 2021-01-08. Some new analysts also
BTIG took its Euronav [EURN] rating to the equivalent of Buy from Neutral, in a research note dated 2021-01-08. Other analysts also revised their coverage,
Deutsche bank took its CME Group [CME] rating to the equivalent of Hold from Buy, and the price target to $196.0, in a research note
BMO Capital took its Life Storage [LSI] rating to the equivalent of Outperform from Market Perform, and the price target to $140, in a research
Evercore ISI Group took its Cerence [CRNC] rating to the equivalent of In-Line from Outperform, and the price target to $105.0, in a research note
Goldman Sachs took its Ping Identity Holding [PING] rating to the equivalent of Buy from Neutral, and the price target to $34.0, in a research
Evercore ISI Group took its Principal Financial Group [PFG] rating to the equivalent of Outperform from In-line, and the price target to $60.0 from $49,
Deutsche bank took its Change Healthcare [CHNG] rating to the equivalent of Hold from Buy, and the price target to $25.75, in a research note
Goldman Sachs took its RenaissanceRe Holdings [RNR] rating to the equivalent of Buy from Neutral, and the price target to $199.0, in a research note
Deutsche bank took its Commercial Metals [CMC] rating to the equivalent of Hold from Buy, and the price target to $22.0, in a research note
Wells Fargo took its Emergent BioSolutions [EBS] rating to the equivalent of Equal-Weight from Overweight, in a research note dated 2021-01-08. Meanwhile, Chardan Capital Markets
BMO Capital took its Sabra Health Care REIT [SBRA] rating to the equivalent of Market Perform from Underperform, and the price target to $19.0, in
Credit Suisse took its Solid Biosciences [SLDB] rating to the equivalent of Neutral from Underperform, and the price target to $7.0, in a research note
SVB Leerink maintained its Accolade [ACCD] rating to the equivalent of Market Perform but changed the price target to $53.0 from $53, in a research
Needham maintained its Revance Therapeutics [RVNC] rating to the equivalent of Buy but changed the price target to $45.0 from $42, in a research note
HC Wainwright & Co. maintained its Krystal Biotech [KRYS] rating to the equivalent of Buy but changed the price target to $84.0 from $68, in
HC Wainwright & Co. maintained its Endeavour Silver [EXK] rating to the equivalent of Buy but changed the price target to $6.75 from $5.75, in
Needham maintained its F5 Networks [FFIV] rating to the equivalent of Buy but changed the price target to $235.0 from $210, in a research note
Benchmark launched its Desktop Metal [DM] rating to the equivalent of Buy and assigned the price target of $28.0, in a research note dated 2021-01-08.
Evercore ISI Group launched its SQZ Biotechnologies [SQZ] rating to the equivalent of Outperform and assigned the price target of $nan, in a research note
Piper Sandler launched its Array Technologies [ARRY] rating to the equivalent of Overweight and assigned the price target of $60.0, in a research note dated
Evercore ISI Group launched its National Storage [NSA] rating to the equivalent of Outperform and assigned the price target of $42.0, in a research note
Needham maintained its Pacira BioSciences [PCRX] rating to the equivalent of Buy but changed the price target to $76.0 from $67, in a research note
SVB Leerink maintained its NeoGenomics [NEO] rating to the equivalent of Outperform but changed the price target to $60.0 from $50, in a research note
RBC Capital took its TRI Pointe Group [TPH] rating to the equivalent of Sector Perform from Outperform, and the price target to $19.0 from $22,
SVB Leerink maintained its Sarepta Therapeutics [SRPT] rating to the equivalent of Outperform but changed the price target to $125.0 from $197, in a research
RBC Capital took its RPM International [RPM] rating to the equivalent of Sector Perform from Outperform, and the price target to $98.0 from $102, in
Chardan Capital launched its Cabaletta Bio [CABA] rating to the equivalent of Buy and assigned the price target of $21.0, in a research note dated
SVB Leerink took its Myovant Sciences [MYOV] rating to the equivalent of Market Perform from Outperform, and the price target to $28.0 from $30, in
DA Davidson maintained its Helen Of Troy [HELE] rating to the equivalent of Buy but changed the price target to $260.0 from $248, in a
KeyBanc launched its Dada Nexus [DADA] rating to the equivalent of Overweight and assigned the price target of $55.0, in a research note dated 2021-01-08.
RBC Capital took its Taylor Morrison Home [TMHC] rating to the equivalent of Sector Perform from Outperform, and the price target to $27.0 from $31,
Jefferies took its Premier [PINC] rating to the equivalent of Hold from Buy, in a research note dated 2021-01-08. Other analysts also revised their coverage,
Evercore ISI Group took its Athene Holding [ATH] rating to the equivalent of In-Line from Outperform, in a research note dated 2021-01-08. Other analysts also
Evercore ISI Group took its Voya Finl [VOYA] rating to the equivalent of In-Line from Outperform, and the price target to $64.0 from $58, in
Needham took its Lam Research [LRCX] rating to the equivalent of Hold from Buy, in a research note dated 2021-01-08. Other analysts also revised their
Keefe, Bruyette & Woods took its Regions Financial [RF] rating to the equivalent of Outperform from Market Perform, and the price target to $18.5 from
Jefferies took its Tenet Healthcare [THC] rating to the equivalent of Buy from Hold, and the price target to $60.0 from $18.5, in a research
Jefferies took its Navios Maritime Partners [NMM] rating to the equivalent of Buy from Hold, and the price target to $15.0 from $7.50, in a
RBC Capital took its Chemours [CC] rating to the equivalent of Outperform from Sector Perform, and the price target to $35.0 from $27, in a
RBC Capital took its Huntsman [HUN] rating to the equivalent of Outperform from Sector Perform, and the price target to $34.0 from $25, in a
Get your daily dose of news with exclusive content, articles, and more at The Market Globalist, a free online newspaper launched in May 2010. They’re young, but ambitious, aiming to deliver engaging and informative content. Contribute your own stories and photos to be part of the community!
Copyright © 2024 Market Globalist , All rights reserved.